RARE DISEASE
Narcolepsy
Narcolepsy
Narcolepsy
Synonyms: Narcolepsy with or without cataplexy
Synonyms: Narcolepsy with or without cataplexy
Synonyms: Narcolepsy with or without cataplexy
Drug discovery
25
drugs
With orphan designations
Overview
Narcolepsy is a chronic neurological disorder characterized by dysregulated sleep-wake cycles, excessive daytime sleepiness (EDS), and disrupted REM sleep. Key features include cataplexy (sudden muscle weakness triggered by emotions) in type 1 (NT1), sleep paralysis, hypnagogic hallucinations, and fragmented nighttime sleep. Diagnosis requires polysomnography and multiple sleep latency testing (MSLT), often supported by hypocretin-1 CSF levels in NT1. While incurable, management combines wake-promoting agents (e.g., modafinil), sodium oxybate, antidepressants, and behavioral strategies like scheduled naps.
Categories: rare neurological diseases
Research Papers
1,666 drug discovery papers about Narcolepsy, with 5 first-in-class and 21 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,666 drug discovery papers about Narcolepsy, with 5 first-in-class and 21 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-08-28 | Therapeutic Prospects of Ketamine for Cataplexy in Narcolepsy Type 1: Evidence from a Human Case and a Murine Model.
Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated. We report the case of a 34-year-old man with narcolepsy type 1, intolerant to standard therapies, who experienced marked and sustained cataplexy reduction with morning intranasal ketamine, with symptom recurrence upon discontinuation. To confirm this observation, ketamine was compared with vehicle in a crossover study in orexin knockout mice implanted for polysomnography. Ketamine dramatically reduced time spent in cataplexy (-76%, p = 0.008) without affecting sleep architecture. These translational findings suggest ketamine as a potential anticataplectic agent, warranting further clinical investigation. ANN NEUROL 2026.
2026-08-27 | Medication Treatment Modulates Sleep Architecture and Cognitive-Related Cortical Hemodynamics in Narcolepsy Type 1.
This exploratory pilot study aimed to evaluate the associations between combination medication treatment and changes in sleep architecture and cognitive task-related cortical hemodynamics in narcolepsy type 1 (NT1). A total of 16 drug-naive NT1 patients were enrolled. All participants underwent polysomnography (PSG), multiple sleep latency test (MSLT), and fNIRS monitoring during Verbal Fluency Test (VFT) and Go/NoGo task before and after pharmacological intervention. Paired nonparametric tests were used to compare differences in PSG, MSLT, and fNIRS parameters before and after treatment. Least absolute shrinkage and selection operator (LASSO) regression and stepwise regression were applied to screen predictors of sleep latency. REM latency and mean sleep latency from MSLT were significantly prolonged, and REM sleep proportion was significantly reduced after medication treatment. During VFT, significant changes in oxyhemoglobin (HbO2) concentration were observed in 5 channels: increased HbO2 levels in frontopolar area, middle temporal gyrus, and subcentral area, and decreased HbO2 levels in retrosplenial cortex (BA 29/30) and dorsolateral prefrontal cortex. No significant HbO2 changes were found during Go/NoGo task. Regression analysis identified that pre-treatment HbO2 change of subcentral area and post-treatment HbO2 change of middle temporal gyrus predicted post-treatment mean sleep latency from MSLT. In this pilot cohort, combination medication therapy was associated with prolongation of sleep latency and task-specific alterations in cortical hemodynamics in NT1 patients. fNIRS-derived parameters show preliminary potential as non-invasive biomarkers for predicting post-treatment sleep latency, which requires validation in larger independent cohorts.
2026-08-26 | Is there a deprescribing regimen for reducing the dose of modafinil in narcolepsy treatment?
No direct evidence for a specific deprescribing regimen for modafinil in narcolepsy was identified. Limited evidence suggests that a drug-holiday approach can reduce side effects and decrease dosage significantly.
2026-08-20 | Sleep-related eating disorder after dose escalation of sodium oxybate in narcolepsy type 1.
Sodium oxybate (SO) is an effective therapy for narcolepsy type 1 (NT1) but has been infrequently linked to complex sleep-related behaviors. We describe a case of NT1 who developed sleep-related eating disorder (SRED) after progressive gradual titration of SO. A 15-year-old female was diagnosed with NT1. Symptoms remained disabling despite high doses of modafinil and venlafaxine, and thus SO was initiated and titrated over months. After increasing to a dose of 4 g twice per night, the family reported episodes of partial arousal with altered consciousness beginning 1-2 h after the first dose, where the patient left the bed, ate large quantities of calorie-dense foods, and appeared unresponsive, before returning to bed again with complete amnesia. These episodes contributed to significant distress for the patient and her family, and notable weight gain. Gradual dose reduction to 7 g/night combined with structured behavioral interventions (dietary modification, bedside snacks, and environmental safety measures) successfully resolved SRED while maintaining excellent cataplexy control, demonstrating that combined management strategies can avoid medication discontinuation.
2026-07-31 | Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders.
Sleep is emerging as a key health topic in modern society. The prevalence of and focus on sleep-wake disorders is increasing, which has led to a large interest from the pharmaceutical industry to develop new treatments targeting sleep biology (that is, drugs that have the potential to mimic normal sleep-wake physiology). The orexin (also known as hypocretin) system is one of the key targets and regulators of sleep and wakefulness. In this Review, we will discuss the mechanisms by which loss of orexin signalling is involved in narcolepsy type 1 and whether loss and/or disruption of orexin signalling might have a role in other sleep disorders such as narcolepsy type 2, idiopathic hypersomnia and obstructive sleep apnoea. We will also describe current and emerging therapies for sleep disorders involving orexin, such as orexin receptor antagonists for insomnia and orexin receptor agonists for narcolepsy.
proteins
2026-09-08 | Orexin pathway modulation in narcolepsy: from Autoimmune mechanisms to nanotechnology enabled therapeutic delivery.
Narcolepsy is a long-term brain disorder caused by disrupted orexin signaling. Orexin neurons sit in the hypothalamus and control the sleep-wake cycle; damage to these neurons leads to narcolepsy. Early evidence pointed to an autoimmune attack on orexin neurons as the main cause. Current treatments - stimulants, antidepressants, sodium oxybate, and scheduled naps - ease symptoms but do not stop the disease, and they often cause side effects such as anxiety, insomnia, and heart problems. Most of these drugs also cannot cross the blood-brain barrier (BBB) to act directly on the hypothalamus. This review examines the autoimmune basis of orexin neuron loss in narcolepsy and looks at how nanotechnology-based delivery systems could carry orexin peptides, genes, or antibodies across the BBB. We highlight priorities for future work: nano-enabled drug delivery, gene and peptide-based therapies, long-term safety data, and treatment approaches tailored to each patient. Progress in this area could shift narcolepsy care from symptom control toward real disease-modifying therapy.
2026-08-24 | Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
The clinical potential of orexin 2 receptor (OX2R) agonism for improving measures of wakefulness and cataplexy in patients with narcolepsy type 1 has been described in a phase 2 study. Here, we aimed to evaluate the safety, tolerability, and efficacy of alixorexton, another oral OX2R agonist, in narcolepsy type 1. In this randomised, double-blind, placebo-controlled, phase 2 trial, adult participants (aged 18-70 years) with narcolepsy type 1 were recruited from 46 hospitals and private research centres across the USA, Europe, and Australia. Participants were centrally randomly assigned (1:1:1:1) in blocks of four via an interactive response technology system stratified by region and baseline weekly cataplexy rate (WCR) to receive 4 mg, 6 mg, or 8 mg tablets of alixorexton or placebo once daily for 6 weeks, followed by an optional 7-week open-label extension. Participants had narcolepsy type 1, diagnosed per the International Classification of Sleep Disorders, Third Edition, and confirmed by overnight polysomnography and the Multiple Sleep Latency Test or cerebrospinal hypocretin-1 concentrations. The sponsor, assessors, investigators, and participants were masked during the randomised double-blind treatment period. Efficacy and safety assessments were conducted in participants who received at least one dose of study drug. The primary endpoint was change from baseline to week 6 in mean sleep latency (MSL) on the Maintenance of Wakefulness Test (MWT). Safety endpoints included treatment-emergent adverse events. This trial was registered with ClinicalTrials.gov (NCT06358950) and is completed. Between May 24, 2024, and May 5, 2025, 153 individuals were screened and 92 participants were randomly assigned to receive alixorexton 4 mg (n=23), 6 mg (n=22), 8 mg (n=24), or placebo (n=23). Mean age was 33·5 years (SD 12·1), 57 (62%) were women, and 35 (38%) were men. At week 6, the observed MSL on the MWT was 2·3 min (SD 2·7) for placebo, 24·0 min (8·7) for alixorexton 4 mg, 25·9 min (9·4) for 6 mg, and 28·2 min (11·4) for 8 mg. Alixorexton improved MSL on the MWT, with a least-squares mean placebo-corrected change from baseline of 22·2 min (95% CI 17·2-27·2) for alixorexton 4 mg, 24·1 min (19·0-29·1) for 6 mg, and 26·0 min (21·0-31·0) for 8 mg (adjusted p=0·0099 for 4 mg, adjusted p<0·0001 for 6 mg and 8 mg). Treatment-emergent adverse events occurring in at least 5% of participants given alixorexton and more frequently than those given placebo up to week 6 were pollakiuria (38 [55%]), insomnia (19 [28%]), salivary hypersecretion (17 [25%]), micturition urgency (ten [14%]), blurred vision (ten [14%]), and hyperhidrosis (five [7%]). In this phase 2 trial, once-daily oral alixorexton provided clinically meaningful improvements at 6 weeks for participants with narcolepsy type 1, including in wakefulness, excessive daytime sleepiness, and cataplexy. The treatment was generally well tolerated, with adverse events consistent with the known on-target effects of OX2R agonists. Together, these findings support the further phase 3 evaluation of alixorexton as a potential therapeutic option for people with narcolepsy type 1. Alkermes.
2026-04-20 | Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine.
Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy. It is increasingly recognized as a multisystem hypothalamic encephalopathy, rooted in the selective loss or dysfunction of orexin neurons, yet extending across motor, psychiatric, metabolic, and autonomic domains. Over the past two decades, convergent genetic, neuropathological, and immunological evidence has positioned narcolepsy type 1 as increasingly consistent with the spectrum of immune-mediated neurological diseases while challenging the validity of current classifications that hinge on cataplexy or multiple sleep latency testing. Borderland phenotypes, variable orexin biology, and post-infectious or secondary forms underscore the limitations of rigid categorical nosologies and support a spectrum-based framework. Advances in immunology, imaging, and systems biology highlight the limitations of purely symptomatic treatment and support the exploration of mechanism-based interventions, including orexin receptor agonism, immune-targeted strategies in early disease, and regenerative or circuit-repair approaches. In this narrative review, based on literature identified through searches of PubMed, Web of Science, and Scopus through December 2025, we synthesize evidence across epidemiology, pathophysiology, diagnosis, and therapy, and propose an integrative clinical algorithm that moves beyond categorical diagnoses toward a phenotype-biomarker-mechanism stratification model. We suggest that narcolepsy should no longer be considered a rare curiosity of sleep medicine but rather a model disorder illuminating the vulnerability of hypothalamic circuits and the complex interplay between sleep, emotion and immunity.
2025-11-19 | Hypothalamic functional connectivity, depressive symptoms, and post-treatment SOREMPs in narcolepsy type 1: links to sleep latency and mediation mechanisms.
Narcolepsy type 1 (NT1) is characterized by sleep-onset rapid eye movement periods (SOREMPs), reflecting dysregulated rapid eye movement (REM) sleep control. Treatment response variability in SOREMP persistence remains poorly understood, particularly regarding hypothalamic functional connectivity (FC) and depressive symptoms. This study investigated clinical, polysomnographic, and neuroimaging differences between NT1 patients with low (0-1) versus high (≥2) post-treatment SOREMPs, and explored whether hypothalamic FC mediates the relationship between depressive symptoms and SOREMPs outcomes. One hundred ten NT1 patients were categorized into low (n = 62) and high (n = 48) post-treatment SOREMPs groups. Demographic, clinical variables (symptoms and questionnaires), and polysomnography (PSG)/multiple sleep latency test (MSLT) parameters were compared. Resting-state fMRI assessed hypothalamic FC with whole-brain regions. LASSO regression modeled associations between FC, sleep latency, and clinical variables, while mediation analysis tested hypothalamic pathways as mediators of depression-SOREMP relationships. High post-treatment SOREMPs patients exhibited shorter pre/post-treatment REM sleep latency, lower post-treatment wakefulness index, and higher depressive symptom prevalence compared to low SOREMPs patients. Hypothalamic FC differed significantly between groups: low SOREMPs patients showed enhanced connectivity in right medial hypothalamus-right thalamus/left precuneus, left medial hypothalamus-left inferior parietal lobule (IPL), and right lateral hypothalamus-left IPL pathways, but reduced connectivity in left lateral hypothalamus-right insula/left anterior cingulate cortex pathways (p < 0.05, GRF-corrected). LASSO regression identified left medial hypothalamus-left IPL FC as a significant predictor of post-treatment MSLT mean sleep latency (β = 0.272, p = 0.001), alongside age (β = -0.256, p = 0.002) and pre-treatment sleep latency (β = 0.392, p < 0.001). Mediation analysis revealed complete mediation by two hypothalamic pathways: depressive symptoms predicted reduced right lateral hypothalamus-left IPL FC (indirect effect: 0.15-1.05), associated with fewer SOREMPs, and increased left lateral hypothalamus-right insula FC (indirect effect: 0.08-1.14), associated with more SOREMPs. Hypothalamic-parietal/insular FC abnormalities link depressive symptoms to post-treatment SOREMP variability in NT1, with specific pathways mediating opposing effects on REM sleep regulation. These findings highlight hypothalamic connectivity as a critical neural substrate for treatment response, integrating sleep-wake and emotional processing networks. Targeting these pathways may improve personalized management for NT1 patients with comorbid depression and treatment-resistant SOREMPs.
2025-11-09 | Association between lipopolysaccharide-binding protein levels and disease severity in pediatric narcolepsy: A cross-sectional study.
Narcolepsy type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness and cataplexy, with increasing evidence suggesting an immune-mediated etiology. Lipopolysaccharide-binding protein (LBP), a key marker of gut-derived immune activation, may play a role in NT1-related systemic inflammation, yet its relationship with disease risk and severity in pediatric NT1 remains unclear. In this cross-sectional study, 96 treatment-naïve pediatric NT1 patients and 90 age- and sex-matched healthy controls were recruited. Serum levels of LBP, C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and lipopolysaccharide (LPS) were measured. Neuropsychiatric assessments included the Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety Scale (HAMA-14), and Hamilton Depression Scale (HAMD-24). Logistic and linear regression analyses were used to evaluate associations between LBP and clinical characteristics. Receiver operating characteristic (ROC) curve analysis was conducted to assess the diagnostic performance of LBP. Pediatric NT1 patients exhibited significantly higher serum levels of LBP, CRP, IL-6, TNF-α, and LPS compared to healthy controls (all p < 0.001). Multivariate logistic regression revealed that LBP (OR = 1.663, 95 % CI: 1.522-1.813, p = 0.016) and IL-6 (OR = 1.912, 95 % CI: 1.702-2.074, p = 0.010) were independent predictors of NT1. LBP levels were negatively associated with hypocretin-1 concentrations and anxiety scores. ROC analysis showed excellent predictive performance of LBP for NT1 (AUC = 0.938, 95 % CI: 0.86-0.99). Elevated serum LBP is significantly associated with increased disease risk and greater symptom burden in pediatric NT1. LBP may serve as a promising inflammatory biomarker reflecting neuroimmune dysregulation and disease severity. Further longitudinal and mechanistic studies are warranted to explore its clinical utility and underlying pathophysiological role.
antibodies
2026-09-03 | A distinct psychotic phenotype in pediatric narcolepsy type 1: a case-control study.
To determine whether pediatric patients with narcolepsy type 1 (NT1) who develop psychotic symptoms exhibit a distinct clinical and sleep-related phenotype compared with those with NT1 without psychosis. We report on clinical and polysomnographic features of nine consecutive pediatric patients observed at our center between 2014 and 2025, who developed psychotic symptoms either at NT1 onset or within one year from NT1 diagnosis, and on a control group of 96 consecutive NT1 patients without evidence of psychotic symptoms. Final psychiatric diagnoses included very-early-onset schizophrenia, psychosis not otherwise specified, psychotic depression, obsessive-compulsive disorders, or autism spectrum disorder with psychotic features. Compared to control NT1 patients, NT1cases with psychosis showed much higher rates of psychiatric family history (OR = 36, 55.6% vs. 2.2%, p < 0.01), lower cerebrospinal fluid hypocretin-1 levels (4.9 ± 9.0 pg/mL vs. 18.9 ± 24.2 pg/mL, p = 0.02) and the following polysomnographic features: shorter nocturnal total sleep time (430.8 ± 86.5min vs. 503.7 ± 76.8min, p = 0.03), lower nocturnal sleep efficiency (75.6 ± 15.6% vs. 89.5 ± 7.6%, p = 0.02), and higher rate of daytime naps (3.7 ± 1.8 vs 2.6 ± 1.7, p = 0.04). Sleep-wake transition metrics indicated increased nocturnal sleep fragmentation, namely higher transition indices between wakefulness and sleep and between wakefulness NREM and REM sleep, respectively. Our findings suggest the presence of a pediatric NT1-psychotic phenotype characterized by more severe hypocretin deficiency and pronounced daytime and nighttime sleep disruption, suggesting that these features may reflect the interaction between hypocretin deficiency and broader neuro-developmental vulnerabilities. Early recognition of this phenotype may guide toward tailored treatment strategies and inform about prognosis in this complex disorder.
2026-08-12 | Immunocyte phenotypes underlying the causal autoimmune features in narcolepsy type 1.
Narcolepsy is a neurological sleep disorder associated with immune response. However, the autoimmune basis for narcolepsy remains unclear. This study aimed to evaluate the causal relationship between immune cells and narcolepsy type 1 (NT1). We used a two-sample Mendelian randomization (MR) method to investigate the associations between 731 immune cell traits and NT1 based on a genome-wide association study (GWAS) database from the FinnGen consortium. The inverse-variance weighted (IVW) method was used as the primary method, followed by sensitivity analyses, including the MR-Egger intercept test, Cochran's Q test, and MR pleiotropy residual sum and outlier (MR-PRESSO). Additional mediation analysis was conducted to investigate the mediating effect of 91 cytokines on immune cells to facilitate the immune processes in NT1. Immune cell traits showed significant causal associations with NT1. Risk-associated traits mainly involved human leukocyte antigen-DR (HLA-DR)-related monocyte phenotypes, T-cell-related traits, natural killer (NK) cell-related traits, and natural killer T (NKT) cell-related traits, whereas protective traits mainly involved CD4+ T-cell-related, plasmacytoid dendritic cell-related, monocyte-related, and B-cell-related phenotypes. Overall, ten immune cell traits were associated with an increased risk of narcolepsy, whereas five were associated with a reduced risk. Mediation analysis further indicated that interleukin-6 (IL-6) mediates the immune-inflammatory pathway linking monocyte-related traits to NT1. These findings remained consistent in all sensitivity analyses. Our study identified immunophenotypes that are related to the development of NT1, providing insight into the autoimmune pathogenesis of NT1 and subsequent immunotherapy.
2026-03-29 | Anti-Ma2 Encephalitis as a Treatable Cause of Narcolepsy Type 1: A Case Report.
BACKGROUND Secondary narcolepsy type 1 (NT1) is an uncommon but increasingly recognized disorder, often associated with autoimmune etiologies that disrupt hypothalamic hypocretin/orexin-producing neurons. Anti-Ma2 encephalitis, a paraneoplastic syndrome commonly linked to testicular tumors, typically involves the limbic system and diencephalon, leading to diverse neuropsychiatric manifestations. While hypersomnia has been reported in a subset of these patients, full syndromic NT1 - characterized by cataplexy, hypocretin deficiency, and objective sleep study abnormalities - remains underrecognized as a presentation. This gap in awareness can delay diagnosis, particularly when sleep-related symptoms predominate. Identifying autoimmune triggers in cases of rapidly progressive hypersomnia is thus critical for guiding appropriate treatment. CASE REPORT A 60-year-old man developed subacute severe daytime sleepiness, cataplexy, episodic limb weakness, and cognitive decline. Polysomnography indicated mild sleep-disordered breathing. The MSLT revealed a mean sleep latency of 6.2 min with 3 SOREMPs. CSF hypocretin-1 was markedly low (22.836 pg/mL). Anti-Ma2 antibodies were positive in both serum and CSF. Neuroimaging showed periventricular white matter changes on MRI and medial temporal hypermetabolism on PET-CT. Immunotherapy with corticosteroids and IVIG resulted in partial neurological improvement and significant reduction in sleepiness. CONCLUSIONS Anti-Ma2 encephalitis is a treatable cause of secondary NT1. Immunotherapy can substantially improve hypersomnolence, although adjunctive symptomatic treatment may be necessary for residual symptoms. Autoimmune evaluation - including antibody panels and hypocretin testing - is crucial in cases of acute/subacute hypersomnia with atypical features to enable timely diagnosis and treatment.
2025-09-25 | Association between cytokines and neuropsychiatric symptoms in paediatric narcolepsy patients: a cross-sectional study.
Narcolepsy is often accompanied by depressive and anxiety symptoms, but the underlying immunological mechanisms remain unclear. Inflammatory cytokines may play a role in both disease onset and psychiatric comorbidities. This study aimed to investigate the association between circulating inflammatory cytokines and neuropsychiatric symptoms in paediatric narcolepsy patients, in order to explore the potential role of immune dysregulation in disease pathogenesis and comorbid mood disorders. This cross-sectional study included 78 paediatric narcolepsy patients and 80 age-matched controls. Cytokine levels and lymphocyte subsets were measured using ELISA and flow cytometry. Depression and anxiety symptoms were assessed using the HAMD-24 and HAMA-14 scales. Logistic regression was used to identify immune markers associated with narcolepsy diagnosis, while linear regression assessed their relationships with depressive and anxiety symptoms. Compared to healthy controls, paediatric narcolepsy patients exhibited significantly elevated levels of IL-6, IL-2, IL-4, TNF-α, IFN-γ, and IL-17 A, alongside reduced IL-10 levels (all P < 0.05). Logistic regression analysis identified IL-6 as an independent risk factor for narcolepsy (OR = 1.46, 95% CI: 1.02-1.93, P = 0.003). Furthermore, IL-6 and the IL-6/IL-10 ratio were positively associated with depressive symptom severity as measured by HAMD-24 scores (P = 0.023 and P = 0.018, respectively). The IFN-γ/IL-4 ratio was independently associated with anxiety symptoms, as reflected by HAMA-14 scores (P = 0.007), after adjusting for confounding variables. These findings suggest that pro-inflammatory cytokines, especially IL-6, are involved in the pathophysiology of paediatric narcolepsy and its related depressive and anxiety symptoms. IL-6 may serve as a potential biomarker and therapeutic target for early intervention.
2025-05-16 | Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches.
Narcolepsy type 1 (NT1) is a chronic orphan neurological sleep disorder characterized by the loss of hypocretin-producing neurons in the lateral hypothalamus, which play a crucial role in wakefulness. Given the genetic association with the HLA-DQB1 * 06:02 allele and environmental links with the 2009 influenza pandemic, many lines of evidence point towards an immune mechanism, notably autoimmunity, underlying the disease pathophysiology. Autoreactive T cells are found in the blood of NT1 patients, and mouse models demonstrate their migratory capacity and contribution in the selective destruction of hypocretin-producing neurons. However, direct evidence for their role in human NT1 pathophysiology remains elusive. In complementing these findings, hypothesis-generating approaches-including multiparametric immune profiling, transcriptomic sequencing and large-scale proteomic of blood and cerebrospinal fluid-have uncovered promising new avenues into the immune system's involvement in NT1. In this review, we explore the mechanisms driving NT1 pathogenesis, emphasizing both hypothesis-driven and hypothesis-generating approaches, and discuss potential future directions that could pave the way for targeted immunotherapies.
gene therapies
2026-02-16 | Bioinformatics identification and experimental validation of hub genes associated with narcolepsy type 1.
Narcolepsy type 1 (NT1) is a chronic neurological disorder with a genetic predisposition, yet its precise molecular pathogenesis remains unclear. Despite increasing recognition of its clinical and genetic basis, the precise molecular mechanisms remain unclear. This study aimed to identify NT1-associated hub genes and investigate their biological functions and interactions through comprehensive bioinformatics analysis, followed by experimental validation. NT1-related microarray data (GSE21592) were retrieved from Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using integrated analysis with R software and the GEO2R platform. Functional enrichment analyses for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were conducted using Database for Annotation, Visualization, and Integrated Discovery online tool. Protein-protein interaction (PPI) networks were constructed using STRING database and visualized with Cytoscape. Quantitative real-time PCR (qRT-PCR) was used to experimentally validate the expression of identified hub genes in NT1 patients. A total of 148 DEGs were identified. GO analysis revealed involvement primarily in biosynthesis, humoral immune response, viral gene expression, oxidoreductase activity, cytoplasmic translation, etc. KEGG analysis showed enrichment in oxidative phosphorylation, ribosomal pathways, thermogenesis, and glutathione metabolism pathways. Five hub genes - CREB1, PIK3R1, MED1, GATA3, and KDM5A - were identified from the PPI network. qRT-PCR validation confirmed significantly reduced expression of these genes in NT1 patients compared to healthy controls. Our study identified and experimentally validated five critical hub genes associated with NT1, providing new insights into its molecular mechanisms and highlighting potential therapeutic targets for future research and clinical intervention strategies.
2025-12-03 | From Normal Variation in Sleep to Clinical Sleep Disorders: Genetic Insights from Over One Million Individuals.
Sleep disorders affect over 30% of the U.S population and are linked to increased disease risk and mortality. However, the genetic architecture of sleep disorders and the overlap of sleep disorders with habitual sleep quality, quantity, and timing have been poorly characterized. In addition, it is unknown if clinical sleep disorders are extremes of habitual sleep traits. Here, we systematically investigated the genetic basis of seven clinical sleep disorder traits, and sixteen medications used for sleep problems in 1,600,000 individuals. We identified 590 genetic associations for sleep apnea, insomnia, restless legs syndrome, narcolepsy and a combined sleep disorder phenotype, of which 367 were previously unreported. Additionally, we discovered 142 genetic associations with sleep medication use. While overall genetic architecture was shared across sleep traits, we found unique genetic factors for the different sleep disorders that reflect fundamentally different biological mechanisms including for example autoimmune processes with narcolepsy and skeletal morphology in sleep apnea. Furthermore, sleep genetic factors showed a broad multi-omic impact on gene and protein expression levels. These findings suggest that while clinical sleep disorders share genetic architecture with each other and with variation in sleep patterns within the general population, they are not simply extremes of normal sleep variation but involve unique biological mechanisms. These results advance our understanding of sleep disorders and suggest potential novel therapeutic targets.
2025-03-03 | [Narcolepsy type 1 and hypocretin neurons].
Narcolepsy is a neurological sleep disorder characterized by a disrupted sleep-wake cycle. The disorder is subdivided into type 1 (NT1) and type 2, where NT1 is distinguished by cataplexy and low hypocretin levels in the cerebrospinal fluid. Despite lacking indisputable evidence, the scientific consensus regarding the disease pathogenesis revolves around an autoimmune destruction of the hypocretin neurons. This is now being challenged by a study proposing that NT1 instead stems from an epigenetic silencing of the hypocretin gene, suggesting reversibility and thereby having profound implications, as pointed out in this review.
2023-04-20 | Genetics and epigenetics of rare hypersomnia.
Herein we focus on connections between genetics and some central disorders of hypersomnolence - narcolepsy types 1 and 2 (NT1, NT2), idiopathic hypersomnia (IH), and Kleine-Levin syndrome (KLS) - for a better understanding of their etiopathogenetic mechanisms and a better diagnostic and therapeutic definition. Gene pleiotropism influences neurological and sleep disorders such as hypersomnia; therefore, genetics allows us to uncover common pathways to different pathologies, with potential new therapeutic perspectives. An important body of evidence has accumulated on NT1 and IH, allowing a better understanding of etiopathogenesis, disease biomarkers, and possible new therapeutic approaches. Further studies are needed in the field of epigenetics, which has a potential role in the modulation of biological specific hypersomnia pathways.
2022-04-08 | Narcolepsy in Parkinson's disease with insulin resistance.
Background: Parkinson's disease (PD) is characterized by its progression of motor-related symptoms such as tremors, rigidity, slowness of movement, and difficulty with walking and balance. Comorbid conditions in PD individuals include insulin resistance (IR) and narcolepsy-like sleep patterns. The intersecting sleep symptoms of both conditions include excessive daytime sleepiness, hallucinations, insomnia, and falling into REM sleep more quickly than an average person. Understanding of the biological basis and relationship of these comorbid disorders with PD may help with early detection and intervention strategies to improve quality of life. Methods: In this study, an integrative genomics and systems biology approach was used to analyze gene expression patterns associated with PD, IR, and narcolepsy in order to identify genes and pathways that may shed light on how these disorders are interrelated. A correlation analysis with known genes associated with these disorders (LRRK2, HLA-DQB1, and HCRT) was used to query microarray data corresponding to brain regions known to be involved in PD and narcolepsy. This includes the hypothalamus, dorsal thalamus, pons, and subcoeruleus nucleus. Risk factor genes for PD, IR, and narcolepsy were also incorporated into the analysis. Results: The PD and narcolepsy signaling networks are connected through insulin and immune system pathways. Important genes and pathways that link PD, narcolepsy, and IR are CACNA1C, CAMK1D, BHLHE41, HMGB1, and AGE-RAGE. Conclusions: We have identified the genetic signatures that link PD with its comorbid disorders, narcolepsy and insulin resistance, from the convergence and intersection of dopaminergic, insulin, and immune system related signaling pathways. These findings may aid in the design of early intervention strategies and treatment regimes for non-motor symptoms in PD patients as well as individuals with diabetes and narcolepsy.
other
2025-05-06 | Orexin Restoration in Narcolepsy: Breakthroughs in Cellular Therapy.
Narcolepsy is a chronic neurodegenerative disorder defined by the selective loss of orexin-producing neurons in the lateral hypothalamus, leading to excessive daytime sleepiness and cataplexy. While pharmacological therapies have evolved to mitigate symptoms, they fail to address the core pathology-orexin deficiency. This narrative review examines the potential of orexin cell transplantation as an innovative therapeutic approach to restore orexin signalling and treat the root cause of narcolepsy. We begin by examining the clinical features, pathophysiology, and diagnostic criteria of narcolepsy, focusing on the essential role of orexins in regulating the sleep-wake cycle and the neurobiological mechanisms underlying cataplexy. The review then explores experimental therapeutic approaches, including hypothalamic tissue grafts, gene therapy, and immortalised orexin-expressing cell lines, highlighting their potential to address the orexin deficit in narcolepsy. While preclinical studies show that transplanted orexin cells can integrate into host neural networks, enhance sleep stability, and decrease the frequency of cataplexy in animal models, several challenges remain. Immortalised orexin cell lines offer a scalable and consistent option for transplantation therapies. However, immune rejection, long-term cell survival, and complete functional integration persist. These translational hurdles must be addressed to bring these therapies to clinical practice. This review underscores the need for continued research to overcome these barriers and optimise cell-based therapies for narcolepsy.
2024-04-20 | 1142 Atypical Cataplexy and Post LP Headaches in POTS with Features of Narcolepsy Type I
Abstract Introduction Postural Orthostatic Tachycardia Syndrome (POTS) consists of orthostatic intolerance upon standing resulting in lightheadedness or fainting. Narcolepsy type I (Narcolepsy with cataplexy) is a disorder of hypersomnolence categorized by cataplexy and impaired hypocretin levels in the hypothalamus. The diagnostic criteria for type 1 narcolepsy include the presence of cataplexy or cerebrospinal fluid orexin-A/hypocretin-1 ≤ 110 pg/mL. Recent data reveals the increased prevalence of POTS in narcolepsy, particularly NT1 phenotype. We present two patients with POTS and features of cataplexy with a normal orexin level. Report of case(s) Patient 1: A 19-y/o Caucasian female presented with excessive daytime sleepiness with the onset of symptoms occurring 5 years before her initial evaluation. The patient describes episodes of “feeling weak” and experiencing symptoms of lightheadedness when “laughing a lot.” A lumber puncture (LP) was conducted by an experienced neurologist using a 22G spinal needle drawing 15cc of CSF The patient described severe headaches lasting for 4 days following the LP, which improved with caffeine, hydration, and analgesics. CSF Orexin= 248 pg/mL. Patient 2: A 22 y/o female presented with severe fatigue, EDS, and POTS against a history of Ehlers-Danlos Syndrome despite a total sleep time of 7-8 hours per night. The patient noted a “loss of coordination” and “sudden muscle weakness when she felt excited and upset while standing, Due to the presence of serotonergic agents and suicidality, a CSF orexin level was drawn using a 24G spinal needle drawing 15cc of CSF. The patient also described severe headaches lasting for a week following the LP, which improved with a blood patch. CSF Orexin= 281 pg/mL. Conclusion Our experience illustrates two important findings about patients with POTS who presented for narcolepsy evaluation: (1) reports of atypical cataplexy may be related to autonomic intolerance compared to cataplexy triggers and is positional in nature, and (2) The prevalence of post-LP headaches in POTS might require prophylactic blood patch and conservative measure to prevent CSF leak/spontaneous intracranial hypotension. Support (if any)
2023-04-27 | Immortal orexin cell transplants restore motor-arousal synchrony during cataplexy.
Waking behaviors such as sitting or standing require suitable levels of muscle tone. But it is unclear how arousal and motor circuits communicate with one another so that appropriate motor tone occurs during wakefulness. Cataplexy is a peculiar condition in which muscle tone is involuntarily lost during normal periods of wakefulness. Cataplexy therefore provides a unique opportunity for identifying the signaling mechanisms that synchronize motor and arousal behaviors. Cataplexy occurs when hypothalamic orexin neurons are lost in narcolepsy; however, it is unclear if motor-arousal decoupling in cataplexy is directly or indirectly caused by orexin cell loss. Here, we used genomic, proteomic, chemogenetic, electrophysiological, and behavioral assays to determine if grafting orexin cells into the brain of cataplectic (i.e., orexin-/-) mice restores normal motor-arousal behaviors by preventing cataplexy. First, we engineered immortalized orexin cells and found that they not only produce and release orexin but also exhibit a gene profile that mimics native orexin neurons. Second, we show that engineered orexin cells thrive and integrate into host tissue when transplanted into the brain of mice. Next, we found that grafting only 200-300 orexin cells into the dorsal raphe nucleus-a region densely innervated by native orexin neurons-reduces cataplexy. Last, we show that real-time chemogenetic activation of orexin cells restores motor-arousal synchrony by preventing cataplexy. We suggest that orexin signaling is critical for arousal-motor synchrony during wakefulness and that the dorsal raphe plays a pivotal role in coupling arousal and motor behaviors.
2023-04-27 | Narcolepsy: Mending a broken neural circuit that controls arousal.
Narcolepsy is a sleep disorder caused by insufficient levels of orexins, with current treatment options addressing symptoms rather than etiology. New research reveals that transplantation of orexin cells in a mouse model of narcolepsy reduces cataplexy.
2023-03-07 | Multiple Sleep Latency Test/Maintenance of Wakefulness Test and Central Hypersomnias: Evolving Diagnostic and Therapeutic Approaches.
Central disorders of hypersomnolence include a spectrum of conditions, such as narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome, in which excessive daytime sleepiness is the primary feature. Subjective testing with tools, such as sleep logs and sleepiness scales, are often helpful in the evaluation of these disorders but do not necessarily correlate well with objective testing, such as polysomnography and multiple sleep latency test and maintenance of wakefulness test. The most recent International Classification of Sleep Disorders-Third Edition has incorporated biomarkers, such as cerebrospinal fluid hypocretin level, into the diagnostic criteria and have restructured the classification of conditions based on our evolved understanding of their underlying pathophysiologic mechanisms. Therapeutic approaches largely consist of behavioral therapy, with a focus on optimizing sleep hygiene, optimizing opportunity for sleep, and strategic napping, along with judicious use of analeptic and anticataleptic agents when necessary. Emerging therapy has revolved around hypocretin-replacement therapy, immunotherapy, and nonhypocretin agents, with the goal of better targeting the underlying pathophysiology of these disorders rather than addressing symptoms. The most novel treatments have targeted the histaminergic system (pitolisant), dopamine reuptake transmission (solriamfetol), and gamma-aminobutyric acid modulation (flumazenil and clarithromycin) to promote wakefulness. Continued research is required for a more solid understanding of the biology of these conditions to develop a more robust armamentarium of therapeutic options.
small molecules
2026-08-28 | Therapeutic Prospects of Ketamine for Cataplexy in Narcolepsy Type 1: Evidence from a Human Case and a Murine Model.
Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated. We report the case of a 34-year-old man with narcolepsy type 1, intolerant to standard therapies, who experienced marked and sustained cataplexy reduction with morning intranasal ketamine, with symptom recurrence upon discontinuation. To confirm this observation, ketamine was compared with vehicle in a crossover study in orexin knockout mice implanted for polysomnography. Ketamine dramatically reduced time spent in cataplexy (-76%, p = 0.008) without affecting sleep architecture. These translational findings suggest ketamine as a potential anticataplectic agent, warranting further clinical investigation. ANN NEUROL 2026.
2026-08-27 | Medication Treatment Modulates Sleep Architecture and Cognitive-Related Cortical Hemodynamics in Narcolepsy Type 1.
This exploratory pilot study aimed to evaluate the associations between combination medication treatment and changes in sleep architecture and cognitive task-related cortical hemodynamics in narcolepsy type 1 (NT1). A total of 16 drug-naive NT1 patients were enrolled. All participants underwent polysomnography (PSG), multiple sleep latency test (MSLT), and fNIRS monitoring during Verbal Fluency Test (VFT) and Go/NoGo task before and after pharmacological intervention. Paired nonparametric tests were used to compare differences in PSG, MSLT, and fNIRS parameters before and after treatment. Least absolute shrinkage and selection operator (LASSO) regression and stepwise regression were applied to screen predictors of sleep latency. REM latency and mean sleep latency from MSLT were significantly prolonged, and REM sleep proportion was significantly reduced after medication treatment. During VFT, significant changes in oxyhemoglobin (HbO2) concentration were observed in 5 channels: increased HbO2 levels in frontopolar area, middle temporal gyrus, and subcentral area, and decreased HbO2 levels in retrosplenial cortex (BA 29/30) and dorsolateral prefrontal cortex. No significant HbO2 changes were found during Go/NoGo task. Regression analysis identified that pre-treatment HbO2 change of subcentral area and post-treatment HbO2 change of middle temporal gyrus predicted post-treatment mean sleep latency from MSLT. In this pilot cohort, combination medication therapy was associated with prolongation of sleep latency and task-specific alterations in cortical hemodynamics in NT1 patients. fNIRS-derived parameters show preliminary potential as non-invasive biomarkers for predicting post-treatment sleep latency, which requires validation in larger independent cohorts.
2026-08-26 | Is there a deprescribing regimen for reducing the dose of modafinil in narcolepsy treatment?
No direct evidence for a specific deprescribing regimen for modafinil in narcolepsy was identified. Limited evidence suggests that a drug-holiday approach can reduce side effects and decrease dosage significantly.
2026-08-20 | Sleep-related eating disorder after dose escalation of sodium oxybate in narcolepsy type 1.
Sodium oxybate (SO) is an effective therapy for narcolepsy type 1 (NT1) but has been infrequently linked to complex sleep-related behaviors. We describe a case of NT1 who developed sleep-related eating disorder (SRED) after progressive gradual titration of SO. A 15-year-old female was diagnosed with NT1. Symptoms remained disabling despite high doses of modafinil and venlafaxine, and thus SO was initiated and titrated over months. After increasing to a dose of 4 g twice per night, the family reported episodes of partial arousal with altered consciousness beginning 1-2 h after the first dose, where the patient left the bed, ate large quantities of calorie-dense foods, and appeared unresponsive, before returning to bed again with complete amnesia. These episodes contributed to significant distress for the patient and her family, and notable weight gain. Gradual dose reduction to 7 g/night combined with structured behavioral interventions (dietary modification, bedside snacks, and environmental safety measures) successfully resolved SRED while maintaining excellent cataplexy control, demonstrating that combined management strategies can avoid medication discontinuation.
2026-07-31 | Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders.
Sleep is emerging as a key health topic in modern society. The prevalence of and focus on sleep-wake disorders is increasing, which has led to a large interest from the pharmaceutical industry to develop new treatments targeting sleep biology (that is, drugs that have the potential to mimic normal sleep-wake physiology). The orexin (also known as hypocretin) system is one of the key targets and regulators of sleep and wakefulness. In this Review, we will discuss the mechanisms by which loss of orexin signalling is involved in narcolepsy type 1 and whether loss and/or disruption of orexin signalling might have a role in other sleep disorders such as narcolepsy type 2, idiopathic hypersomnia and obstructive sleep apnoea. We will also describe current and emerging therapies for sleep disorders involving orexin, such as orexin receptor antagonists for insomnia and orexin receptor agonists for narcolepsy.
proteins
2026-09-08 | Orexin pathway modulation in narcolepsy: from Autoimmune mechanisms to nanotechnology enabled therapeutic delivery.
Narcolepsy is a long-term brain disorder caused by disrupted orexin signaling. Orexin neurons sit in the hypothalamus and control the sleep-wake cycle; damage to these neurons leads to narcolepsy. Early evidence pointed to an autoimmune attack on orexin neurons as the main cause. Current treatments - stimulants, antidepressants, sodium oxybate, and scheduled naps - ease symptoms but do not stop the disease, and they often cause side effects such as anxiety, insomnia, and heart problems. Most of these drugs also cannot cross the blood-brain barrier (BBB) to act directly on the hypothalamus. This review examines the autoimmune basis of orexin neuron loss in narcolepsy and looks at how nanotechnology-based delivery systems could carry orexin peptides, genes, or antibodies across the BBB. We highlight priorities for future work: nano-enabled drug delivery, gene and peptide-based therapies, long-term safety data, and treatment approaches tailored to each patient. Progress in this area could shift narcolepsy care from symptom control toward real disease-modifying therapy.
2026-08-24 | Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
The clinical potential of orexin 2 receptor (OX2R) agonism for improving measures of wakefulness and cataplexy in patients with narcolepsy type 1 has been described in a phase 2 study. Here, we aimed to evaluate the safety, tolerability, and efficacy of alixorexton, another oral OX2R agonist, in narcolepsy type 1. In this randomised, double-blind, placebo-controlled, phase 2 trial, adult participants (aged 18-70 years) with narcolepsy type 1 were recruited from 46 hospitals and private research centres across the USA, Europe, and Australia. Participants were centrally randomly assigned (1:1:1:1) in blocks of four via an interactive response technology system stratified by region and baseline weekly cataplexy rate (WCR) to receive 4 mg, 6 mg, or 8 mg tablets of alixorexton or placebo once daily for 6 weeks, followed by an optional 7-week open-label extension. Participants had narcolepsy type 1, diagnosed per the International Classification of Sleep Disorders, Third Edition, and confirmed by overnight polysomnography and the Multiple Sleep Latency Test or cerebrospinal hypocretin-1 concentrations. The sponsor, assessors, investigators, and participants were masked during the randomised double-blind treatment period. Efficacy and safety assessments were conducted in participants who received at least one dose of study drug. The primary endpoint was change from baseline to week 6 in mean sleep latency (MSL) on the Maintenance of Wakefulness Test (MWT). Safety endpoints included treatment-emergent adverse events. This trial was registered with ClinicalTrials.gov (NCT06358950) and is completed. Between May 24, 2024, and May 5, 2025, 153 individuals were screened and 92 participants were randomly assigned to receive alixorexton 4 mg (n=23), 6 mg (n=22), 8 mg (n=24), or placebo (n=23). Mean age was 33·5 years (SD 12·1), 57 (62%) were women, and 35 (38%) were men. At week 6, the observed MSL on the MWT was 2·3 min (SD 2·7) for placebo, 24·0 min (8·7) for alixorexton 4 mg, 25·9 min (9·4) for 6 mg, and 28·2 min (11·4) for 8 mg. Alixorexton improved MSL on the MWT, with a least-squares mean placebo-corrected change from baseline of 22·2 min (95% CI 17·2-27·2) for alixorexton 4 mg, 24·1 min (19·0-29·1) for 6 mg, and 26·0 min (21·0-31·0) for 8 mg (adjusted p=0·0099 for 4 mg, adjusted p<0·0001 for 6 mg and 8 mg). Treatment-emergent adverse events occurring in at least 5% of participants given alixorexton and more frequently than those given placebo up to week 6 were pollakiuria (38 [55%]), insomnia (19 [28%]), salivary hypersecretion (17 [25%]), micturition urgency (ten [14%]), blurred vision (ten [14%]), and hyperhidrosis (five [7%]). In this phase 2 trial, once-daily oral alixorexton provided clinically meaningful improvements at 6 weeks for participants with narcolepsy type 1, including in wakefulness, excessive daytime sleepiness, and cataplexy. The treatment was generally well tolerated, with adverse events consistent with the known on-target effects of OX2R agonists. Together, these findings support the further phase 3 evaluation of alixorexton as a potential therapeutic option for people with narcolepsy type 1. Alkermes.
2026-04-20 | Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine.
Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy. It is increasingly recognized as a multisystem hypothalamic encephalopathy, rooted in the selective loss or dysfunction of orexin neurons, yet extending across motor, psychiatric, metabolic, and autonomic domains. Over the past two decades, convergent genetic, neuropathological, and immunological evidence has positioned narcolepsy type 1 as increasingly consistent with the spectrum of immune-mediated neurological diseases while challenging the validity of current classifications that hinge on cataplexy or multiple sleep latency testing. Borderland phenotypes, variable orexin biology, and post-infectious or secondary forms underscore the limitations of rigid categorical nosologies and support a spectrum-based framework. Advances in immunology, imaging, and systems biology highlight the limitations of purely symptomatic treatment and support the exploration of mechanism-based interventions, including orexin receptor agonism, immune-targeted strategies in early disease, and regenerative or circuit-repair approaches. In this narrative review, based on literature identified through searches of PubMed, Web of Science, and Scopus through December 2025, we synthesize evidence across epidemiology, pathophysiology, diagnosis, and therapy, and propose an integrative clinical algorithm that moves beyond categorical diagnoses toward a phenotype-biomarker-mechanism stratification model. We suggest that narcolepsy should no longer be considered a rare curiosity of sleep medicine but rather a model disorder illuminating the vulnerability of hypothalamic circuits and the complex interplay between sleep, emotion and immunity.
2025-11-19 | Hypothalamic functional connectivity, depressive symptoms, and post-treatment SOREMPs in narcolepsy type 1: links to sleep latency and mediation mechanisms.
Narcolepsy type 1 (NT1) is characterized by sleep-onset rapid eye movement periods (SOREMPs), reflecting dysregulated rapid eye movement (REM) sleep control. Treatment response variability in SOREMP persistence remains poorly understood, particularly regarding hypothalamic functional connectivity (FC) and depressive symptoms. This study investigated clinical, polysomnographic, and neuroimaging differences between NT1 patients with low (0-1) versus high (≥2) post-treatment SOREMPs, and explored whether hypothalamic FC mediates the relationship between depressive symptoms and SOREMPs outcomes. One hundred ten NT1 patients were categorized into low (n = 62) and high (n = 48) post-treatment SOREMPs groups. Demographic, clinical variables (symptoms and questionnaires), and polysomnography (PSG)/multiple sleep latency test (MSLT) parameters were compared. Resting-state fMRI assessed hypothalamic FC with whole-brain regions. LASSO regression modeled associations between FC, sleep latency, and clinical variables, while mediation analysis tested hypothalamic pathways as mediators of depression-SOREMP relationships. High post-treatment SOREMPs patients exhibited shorter pre/post-treatment REM sleep latency, lower post-treatment wakefulness index, and higher depressive symptom prevalence compared to low SOREMPs patients. Hypothalamic FC differed significantly between groups: low SOREMPs patients showed enhanced connectivity in right medial hypothalamus-right thalamus/left precuneus, left medial hypothalamus-left inferior parietal lobule (IPL), and right lateral hypothalamus-left IPL pathways, but reduced connectivity in left lateral hypothalamus-right insula/left anterior cingulate cortex pathways (p < 0.05, GRF-corrected). LASSO regression identified left medial hypothalamus-left IPL FC as a significant predictor of post-treatment MSLT mean sleep latency (β = 0.272, p = 0.001), alongside age (β = -0.256, p = 0.002) and pre-treatment sleep latency (β = 0.392, p < 0.001). Mediation analysis revealed complete mediation by two hypothalamic pathways: depressive symptoms predicted reduced right lateral hypothalamus-left IPL FC (indirect effect: 0.15-1.05), associated with fewer SOREMPs, and increased left lateral hypothalamus-right insula FC (indirect effect: 0.08-1.14), associated with more SOREMPs. Hypothalamic-parietal/insular FC abnormalities link depressive symptoms to post-treatment SOREMP variability in NT1, with specific pathways mediating opposing effects on REM sleep regulation. These findings highlight hypothalamic connectivity as a critical neural substrate for treatment response, integrating sleep-wake and emotional processing networks. Targeting these pathways may improve personalized management for NT1 patients with comorbid depression and treatment-resistant SOREMPs.
2025-11-09 | Association between lipopolysaccharide-binding protein levels and disease severity in pediatric narcolepsy: A cross-sectional study.
Narcolepsy type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness and cataplexy, with increasing evidence suggesting an immune-mediated etiology. Lipopolysaccharide-binding protein (LBP), a key marker of gut-derived immune activation, may play a role in NT1-related systemic inflammation, yet its relationship with disease risk and severity in pediatric NT1 remains unclear. In this cross-sectional study, 96 treatment-naïve pediatric NT1 patients and 90 age- and sex-matched healthy controls were recruited. Serum levels of LBP, C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and lipopolysaccharide (LPS) were measured. Neuropsychiatric assessments included the Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety Scale (HAMA-14), and Hamilton Depression Scale (HAMD-24). Logistic and linear regression analyses were used to evaluate associations between LBP and clinical characteristics. Receiver operating characteristic (ROC) curve analysis was conducted to assess the diagnostic performance of LBP. Pediatric NT1 patients exhibited significantly higher serum levels of LBP, CRP, IL-6, TNF-α, and LPS compared to healthy controls (all p < 0.001). Multivariate logistic regression revealed that LBP (OR = 1.663, 95 % CI: 1.522-1.813, p = 0.016) and IL-6 (OR = 1.912, 95 % CI: 1.702-2.074, p = 0.010) were independent predictors of NT1. LBP levels were negatively associated with hypocretin-1 concentrations and anxiety scores. ROC analysis showed excellent predictive performance of LBP for NT1 (AUC = 0.938, 95 % CI: 0.86-0.99). Elevated serum LBP is significantly associated with increased disease risk and greater symptom burden in pediatric NT1. LBP may serve as a promising inflammatory biomarker reflecting neuroimmune dysregulation and disease severity. Further longitudinal and mechanistic studies are warranted to explore its clinical utility and underlying pathophysiological role.
antibodies
2026-09-03 | A distinct psychotic phenotype in pediatric narcolepsy type 1: a case-control study.
To determine whether pediatric patients with narcolepsy type 1 (NT1) who develop psychotic symptoms exhibit a distinct clinical and sleep-related phenotype compared with those with NT1 without psychosis. We report on clinical and polysomnographic features of nine consecutive pediatric patients observed at our center between 2014 and 2025, who developed psychotic symptoms either at NT1 onset or within one year from NT1 diagnosis, and on a control group of 96 consecutive NT1 patients without evidence of psychotic symptoms. Final psychiatric diagnoses included very-early-onset schizophrenia, psychosis not otherwise specified, psychotic depression, obsessive-compulsive disorders, or autism spectrum disorder with psychotic features. Compared to control NT1 patients, NT1cases with psychosis showed much higher rates of psychiatric family history (OR = 36, 55.6% vs. 2.2%, p < 0.01), lower cerebrospinal fluid hypocretin-1 levels (4.9 ± 9.0 pg/mL vs. 18.9 ± 24.2 pg/mL, p = 0.02) and the following polysomnographic features: shorter nocturnal total sleep time (430.8 ± 86.5min vs. 503.7 ± 76.8min, p = 0.03), lower nocturnal sleep efficiency (75.6 ± 15.6% vs. 89.5 ± 7.6%, p = 0.02), and higher rate of daytime naps (3.7 ± 1.8 vs 2.6 ± 1.7, p = 0.04). Sleep-wake transition metrics indicated increased nocturnal sleep fragmentation, namely higher transition indices between wakefulness and sleep and between wakefulness NREM and REM sleep, respectively. Our findings suggest the presence of a pediatric NT1-psychotic phenotype characterized by more severe hypocretin deficiency and pronounced daytime and nighttime sleep disruption, suggesting that these features may reflect the interaction between hypocretin deficiency and broader neuro-developmental vulnerabilities. Early recognition of this phenotype may guide toward tailored treatment strategies and inform about prognosis in this complex disorder.
2026-08-12 | Immunocyte phenotypes underlying the causal autoimmune features in narcolepsy type 1.
Narcolepsy is a neurological sleep disorder associated with immune response. However, the autoimmune basis for narcolepsy remains unclear. This study aimed to evaluate the causal relationship between immune cells and narcolepsy type 1 (NT1). We used a two-sample Mendelian randomization (MR) method to investigate the associations between 731 immune cell traits and NT1 based on a genome-wide association study (GWAS) database from the FinnGen consortium. The inverse-variance weighted (IVW) method was used as the primary method, followed by sensitivity analyses, including the MR-Egger intercept test, Cochran's Q test, and MR pleiotropy residual sum and outlier (MR-PRESSO). Additional mediation analysis was conducted to investigate the mediating effect of 91 cytokines on immune cells to facilitate the immune processes in NT1. Immune cell traits showed significant causal associations with NT1. Risk-associated traits mainly involved human leukocyte antigen-DR (HLA-DR)-related monocyte phenotypes, T-cell-related traits, natural killer (NK) cell-related traits, and natural killer T (NKT) cell-related traits, whereas protective traits mainly involved CD4+ T-cell-related, plasmacytoid dendritic cell-related, monocyte-related, and B-cell-related phenotypes. Overall, ten immune cell traits were associated with an increased risk of narcolepsy, whereas five were associated with a reduced risk. Mediation analysis further indicated that interleukin-6 (IL-6) mediates the immune-inflammatory pathway linking monocyte-related traits to NT1. These findings remained consistent in all sensitivity analyses. Our study identified immunophenotypes that are related to the development of NT1, providing insight into the autoimmune pathogenesis of NT1 and subsequent immunotherapy.
2026-03-29 | Anti-Ma2 Encephalitis as a Treatable Cause of Narcolepsy Type 1: A Case Report.
BACKGROUND Secondary narcolepsy type 1 (NT1) is an uncommon but increasingly recognized disorder, often associated with autoimmune etiologies that disrupt hypothalamic hypocretin/orexin-producing neurons. Anti-Ma2 encephalitis, a paraneoplastic syndrome commonly linked to testicular tumors, typically involves the limbic system and diencephalon, leading to diverse neuropsychiatric manifestations. While hypersomnia has been reported in a subset of these patients, full syndromic NT1 - characterized by cataplexy, hypocretin deficiency, and objective sleep study abnormalities - remains underrecognized as a presentation. This gap in awareness can delay diagnosis, particularly when sleep-related symptoms predominate. Identifying autoimmune triggers in cases of rapidly progressive hypersomnia is thus critical for guiding appropriate treatment. CASE REPORT A 60-year-old man developed subacute severe daytime sleepiness, cataplexy, episodic limb weakness, and cognitive decline. Polysomnography indicated mild sleep-disordered breathing. The MSLT revealed a mean sleep latency of 6.2 min with 3 SOREMPs. CSF hypocretin-1 was markedly low (22.836 pg/mL). Anti-Ma2 antibodies were positive in both serum and CSF. Neuroimaging showed periventricular white matter changes on MRI and medial temporal hypermetabolism on PET-CT. Immunotherapy with corticosteroids and IVIG resulted in partial neurological improvement and significant reduction in sleepiness. CONCLUSIONS Anti-Ma2 encephalitis is a treatable cause of secondary NT1. Immunotherapy can substantially improve hypersomnolence, although adjunctive symptomatic treatment may be necessary for residual symptoms. Autoimmune evaluation - including antibody panels and hypocretin testing - is crucial in cases of acute/subacute hypersomnia with atypical features to enable timely diagnosis and treatment.
2025-09-25 | Association between cytokines and neuropsychiatric symptoms in paediatric narcolepsy patients: a cross-sectional study.
Narcolepsy is often accompanied by depressive and anxiety symptoms, but the underlying immunological mechanisms remain unclear. Inflammatory cytokines may play a role in both disease onset and psychiatric comorbidities. This study aimed to investigate the association between circulating inflammatory cytokines and neuropsychiatric symptoms in paediatric narcolepsy patients, in order to explore the potential role of immune dysregulation in disease pathogenesis and comorbid mood disorders. This cross-sectional study included 78 paediatric narcolepsy patients and 80 age-matched controls. Cytokine levels and lymphocyte subsets were measured using ELISA and flow cytometry. Depression and anxiety symptoms were assessed using the HAMD-24 and HAMA-14 scales. Logistic regression was used to identify immune markers associated with narcolepsy diagnosis, while linear regression assessed their relationships with depressive and anxiety symptoms. Compared to healthy controls, paediatric narcolepsy patients exhibited significantly elevated levels of IL-6, IL-2, IL-4, TNF-α, IFN-γ, and IL-17 A, alongside reduced IL-10 levels (all P < 0.05). Logistic regression analysis identified IL-6 as an independent risk factor for narcolepsy (OR = 1.46, 95% CI: 1.02-1.93, P = 0.003). Furthermore, IL-6 and the IL-6/IL-10 ratio were positively associated with depressive symptom severity as measured by HAMD-24 scores (P = 0.023 and P = 0.018, respectively). The IFN-γ/IL-4 ratio was independently associated with anxiety symptoms, as reflected by HAMA-14 scores (P = 0.007), after adjusting for confounding variables. These findings suggest that pro-inflammatory cytokines, especially IL-6, are involved in the pathophysiology of paediatric narcolepsy and its related depressive and anxiety symptoms. IL-6 may serve as a potential biomarker and therapeutic target for early intervention.
2025-05-16 | Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches.
Narcolepsy type 1 (NT1) is a chronic orphan neurological sleep disorder characterized by the loss of hypocretin-producing neurons in the lateral hypothalamus, which play a crucial role in wakefulness. Given the genetic association with the HLA-DQB1 * 06:02 allele and environmental links with the 2009 influenza pandemic, many lines of evidence point towards an immune mechanism, notably autoimmunity, underlying the disease pathophysiology. Autoreactive T cells are found in the blood of NT1 patients, and mouse models demonstrate their migratory capacity and contribution in the selective destruction of hypocretin-producing neurons. However, direct evidence for their role in human NT1 pathophysiology remains elusive. In complementing these findings, hypothesis-generating approaches-including multiparametric immune profiling, transcriptomic sequencing and large-scale proteomic of blood and cerebrospinal fluid-have uncovered promising new avenues into the immune system's involvement in NT1. In this review, we explore the mechanisms driving NT1 pathogenesis, emphasizing both hypothesis-driven and hypothesis-generating approaches, and discuss potential future directions that could pave the way for targeted immunotherapies.
gene therapies
2026-02-16 | Bioinformatics identification and experimental validation of hub genes associated with narcolepsy type 1.
Narcolepsy type 1 (NT1) is a chronic neurological disorder with a genetic predisposition, yet its precise molecular pathogenesis remains unclear. Despite increasing recognition of its clinical and genetic basis, the precise molecular mechanisms remain unclear. This study aimed to identify NT1-associated hub genes and investigate their biological functions and interactions through comprehensive bioinformatics analysis, followed by experimental validation. NT1-related microarray data (GSE21592) were retrieved from Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using integrated analysis with R software and the GEO2R platform. Functional enrichment analyses for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were conducted using Database for Annotation, Visualization, and Integrated Discovery online tool. Protein-protein interaction (PPI) networks were constructed using STRING database and visualized with Cytoscape. Quantitative real-time PCR (qRT-PCR) was used to experimentally validate the expression of identified hub genes in NT1 patients. A total of 148 DEGs were identified. GO analysis revealed involvement primarily in biosynthesis, humoral immune response, viral gene expression, oxidoreductase activity, cytoplasmic translation, etc. KEGG analysis showed enrichment in oxidative phosphorylation, ribosomal pathways, thermogenesis, and glutathione metabolism pathways. Five hub genes - CREB1, PIK3R1, MED1, GATA3, and KDM5A - were identified from the PPI network. qRT-PCR validation confirmed significantly reduced expression of these genes in NT1 patients compared to healthy controls. Our study identified and experimentally validated five critical hub genes associated with NT1, providing new insights into its molecular mechanisms and highlighting potential therapeutic targets for future research and clinical intervention strategies.
2025-12-03 | From Normal Variation in Sleep to Clinical Sleep Disorders: Genetic Insights from Over One Million Individuals.
Sleep disorders affect over 30% of the U.S population and are linked to increased disease risk and mortality. However, the genetic architecture of sleep disorders and the overlap of sleep disorders with habitual sleep quality, quantity, and timing have been poorly characterized. In addition, it is unknown if clinical sleep disorders are extremes of habitual sleep traits. Here, we systematically investigated the genetic basis of seven clinical sleep disorder traits, and sixteen medications used for sleep problems in 1,600,000 individuals. We identified 590 genetic associations for sleep apnea, insomnia, restless legs syndrome, narcolepsy and a combined sleep disorder phenotype, of which 367 were previously unreported. Additionally, we discovered 142 genetic associations with sleep medication use. While overall genetic architecture was shared across sleep traits, we found unique genetic factors for the different sleep disorders that reflect fundamentally different biological mechanisms including for example autoimmune processes with narcolepsy and skeletal morphology in sleep apnea. Furthermore, sleep genetic factors showed a broad multi-omic impact on gene and protein expression levels. These findings suggest that while clinical sleep disorders share genetic architecture with each other and with variation in sleep patterns within the general population, they are not simply extremes of normal sleep variation but involve unique biological mechanisms. These results advance our understanding of sleep disorders and suggest potential novel therapeutic targets.
2025-03-03 | [Narcolepsy type 1 and hypocretin neurons].
Narcolepsy is a neurological sleep disorder characterized by a disrupted sleep-wake cycle. The disorder is subdivided into type 1 (NT1) and type 2, where NT1 is distinguished by cataplexy and low hypocretin levels in the cerebrospinal fluid. Despite lacking indisputable evidence, the scientific consensus regarding the disease pathogenesis revolves around an autoimmune destruction of the hypocretin neurons. This is now being challenged by a study proposing that NT1 instead stems from an epigenetic silencing of the hypocretin gene, suggesting reversibility and thereby having profound implications, as pointed out in this review.
2023-04-20 | Genetics and epigenetics of rare hypersomnia.
Herein we focus on connections between genetics and some central disorders of hypersomnolence - narcolepsy types 1 and 2 (NT1, NT2), idiopathic hypersomnia (IH), and Kleine-Levin syndrome (KLS) - for a better understanding of their etiopathogenetic mechanisms and a better diagnostic and therapeutic definition. Gene pleiotropism influences neurological and sleep disorders such as hypersomnia; therefore, genetics allows us to uncover common pathways to different pathologies, with potential new therapeutic perspectives. An important body of evidence has accumulated on NT1 and IH, allowing a better understanding of etiopathogenesis, disease biomarkers, and possible new therapeutic approaches. Further studies are needed in the field of epigenetics, which has a potential role in the modulation of biological specific hypersomnia pathways.
2022-04-08 | Narcolepsy in Parkinson's disease with insulin resistance.
Background: Parkinson's disease (PD) is characterized by its progression of motor-related symptoms such as tremors, rigidity, slowness of movement, and difficulty with walking and balance. Comorbid conditions in PD individuals include insulin resistance (IR) and narcolepsy-like sleep patterns. The intersecting sleep symptoms of both conditions include excessive daytime sleepiness, hallucinations, insomnia, and falling into REM sleep more quickly than an average person. Understanding of the biological basis and relationship of these comorbid disorders with PD may help with early detection and intervention strategies to improve quality of life. Methods: In this study, an integrative genomics and systems biology approach was used to analyze gene expression patterns associated with PD, IR, and narcolepsy in order to identify genes and pathways that may shed light on how these disorders are interrelated. A correlation analysis with known genes associated with these disorders (LRRK2, HLA-DQB1, and HCRT) was used to query microarray data corresponding to brain regions known to be involved in PD and narcolepsy. This includes the hypothalamus, dorsal thalamus, pons, and subcoeruleus nucleus. Risk factor genes for PD, IR, and narcolepsy were also incorporated into the analysis. Results: The PD and narcolepsy signaling networks are connected through insulin and immune system pathways. Important genes and pathways that link PD, narcolepsy, and IR are CACNA1C, CAMK1D, BHLHE41, HMGB1, and AGE-RAGE. Conclusions: We have identified the genetic signatures that link PD with its comorbid disorders, narcolepsy and insulin resistance, from the convergence and intersection of dopaminergic, insulin, and immune system related signaling pathways. These findings may aid in the design of early intervention strategies and treatment regimes for non-motor symptoms in PD patients as well as individuals with diabetes and narcolepsy.
other
2025-05-06 | Orexin Restoration in Narcolepsy: Breakthroughs in Cellular Therapy.
Narcolepsy is a chronic neurodegenerative disorder defined by the selective loss of orexin-producing neurons in the lateral hypothalamus, leading to excessive daytime sleepiness and cataplexy. While pharmacological therapies have evolved to mitigate symptoms, they fail to address the core pathology-orexin deficiency. This narrative review examines the potential of orexin cell transplantation as an innovative therapeutic approach to restore orexin signalling and treat the root cause of narcolepsy. We begin by examining the clinical features, pathophysiology, and diagnostic criteria of narcolepsy, focusing on the essential role of orexins in regulating the sleep-wake cycle and the neurobiological mechanisms underlying cataplexy. The review then explores experimental therapeutic approaches, including hypothalamic tissue grafts, gene therapy, and immortalised orexin-expressing cell lines, highlighting their potential to address the orexin deficit in narcolepsy. While preclinical studies show that transplanted orexin cells can integrate into host neural networks, enhance sleep stability, and decrease the frequency of cataplexy in animal models, several challenges remain. Immortalised orexin cell lines offer a scalable and consistent option for transplantation therapies. However, immune rejection, long-term cell survival, and complete functional integration persist. These translational hurdles must be addressed to bring these therapies to clinical practice. This review underscores the need for continued research to overcome these barriers and optimise cell-based therapies for narcolepsy.
2024-04-20 | 1142 Atypical Cataplexy and Post LP Headaches in POTS with Features of Narcolepsy Type I
Abstract Introduction Postural Orthostatic Tachycardia Syndrome (POTS) consists of orthostatic intolerance upon standing resulting in lightheadedness or fainting. Narcolepsy type I (Narcolepsy with cataplexy) is a disorder of hypersomnolence categorized by cataplexy and impaired hypocretin levels in the hypothalamus. The diagnostic criteria for type 1 narcolepsy include the presence of cataplexy or cerebrospinal fluid orexin-A/hypocretin-1 ≤ 110 pg/mL. Recent data reveals the increased prevalence of POTS in narcolepsy, particularly NT1 phenotype. We present two patients with POTS and features of cataplexy with a normal orexin level. Report of case(s) Patient 1: A 19-y/o Caucasian female presented with excessive daytime sleepiness with the onset of symptoms occurring 5 years before her initial evaluation. The patient describes episodes of “feeling weak” and experiencing symptoms of lightheadedness when “laughing a lot.” A lumber puncture (LP) was conducted by an experienced neurologist using a 22G spinal needle drawing 15cc of CSF The patient described severe headaches lasting for 4 days following the LP, which improved with caffeine, hydration, and analgesics. CSF Orexin= 248 pg/mL. Patient 2: A 22 y/o female presented with severe fatigue, EDS, and POTS against a history of Ehlers-Danlos Syndrome despite a total sleep time of 7-8 hours per night. The patient noted a “loss of coordination” and “sudden muscle weakness when she felt excited and upset while standing, Due to the presence of serotonergic agents and suicidality, a CSF orexin level was drawn using a 24G spinal needle drawing 15cc of CSF. The patient also described severe headaches lasting for a week following the LP, which improved with a blood patch. CSF Orexin= 281 pg/mL. Conclusion Our experience illustrates two important findings about patients with POTS who presented for narcolepsy evaluation: (1) reports of atypical cataplexy may be related to autonomic intolerance compared to cataplexy triggers and is positional in nature, and (2) The prevalence of post-LP headaches in POTS might require prophylactic blood patch and conservative measure to prevent CSF leak/spontaneous intracranial hypotension. Support (if any)
2023-04-27 | Immortal orexin cell transplants restore motor-arousal synchrony during cataplexy.
Waking behaviors such as sitting or standing require suitable levels of muscle tone. But it is unclear how arousal and motor circuits communicate with one another so that appropriate motor tone occurs during wakefulness. Cataplexy is a peculiar condition in which muscle tone is involuntarily lost during normal periods of wakefulness. Cataplexy therefore provides a unique opportunity for identifying the signaling mechanisms that synchronize motor and arousal behaviors. Cataplexy occurs when hypothalamic orexin neurons are lost in narcolepsy; however, it is unclear if motor-arousal decoupling in cataplexy is directly or indirectly caused by orexin cell loss. Here, we used genomic, proteomic, chemogenetic, electrophysiological, and behavioral assays to determine if grafting orexin cells into the brain of cataplectic (i.e., orexin-/-) mice restores normal motor-arousal behaviors by preventing cataplexy. First, we engineered immortalized orexin cells and found that they not only produce and release orexin but also exhibit a gene profile that mimics native orexin neurons. Second, we show that engineered orexin cells thrive and integrate into host tissue when transplanted into the brain of mice. Next, we found that grafting only 200-300 orexin cells into the dorsal raphe nucleus-a region densely innervated by native orexin neurons-reduces cataplexy. Last, we show that real-time chemogenetic activation of orexin cells restores motor-arousal synchrony by preventing cataplexy. We suggest that orexin signaling is critical for arousal-motor synchrony during wakefulness and that the dorsal raphe plays a pivotal role in coupling arousal and motor behaviors.
2023-04-27 | Narcolepsy: Mending a broken neural circuit that controls arousal.
Narcolepsy is a sleep disorder caused by insufficient levels of orexins, with current treatment options addressing symptoms rather than etiology. New research reveals that transplantation of orexin cells in a mouse model of narcolepsy reduces cataplexy.
2023-03-07 | Multiple Sleep Latency Test/Maintenance of Wakefulness Test and Central Hypersomnias: Evolving Diagnostic and Therapeutic Approaches.
Central disorders of hypersomnolence include a spectrum of conditions, such as narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome, in which excessive daytime sleepiness is the primary feature. Subjective testing with tools, such as sleep logs and sleepiness scales, are often helpful in the evaluation of these disorders but do not necessarily correlate well with objective testing, such as polysomnography and multiple sleep latency test and maintenance of wakefulness test. The most recent International Classification of Sleep Disorders-Third Edition has incorporated biomarkers, such as cerebrospinal fluid hypocretin level, into the diagnostic criteria and have restructured the classification of conditions based on our evolved understanding of their underlying pathophysiologic mechanisms. Therapeutic approaches largely consist of behavioral therapy, with a focus on optimizing sleep hygiene, optimizing opportunity for sleep, and strategic napping, along with judicious use of analeptic and anticataleptic agents when necessary. Emerging therapy has revolved around hypocretin-replacement therapy, immunotherapy, and nonhypocretin agents, with the goal of better targeting the underlying pathophysiology of these disorders rather than addressing symptoms. The most novel treatments have targeted the histaminergic system (pitolisant), dopamine reuptake transmission (solriamfetol), and gamma-aminobutyric acid modulation (flumazenil and clarithromycin) to promote wakefulness. Continued research is required for a more solid understanding of the biology of these conditions to develop a more robust armamentarium of therapeutic options.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
25 orphan drug designations for Narcolepsy, including 9 approved therapies.
25 orphan drug designations for Narcolepsy, including 9 approved therapies.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
Alixorexton | small molecules | EMA | Alkermes Pharma Ireland Limited | |
N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3',5'-trifluoro[1,1'-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide | small molecules | EMA | Takeda Pharma A/S | |
Sodium oxybate | small molecules | EMA | Avadel Ireland | |
Tropatepine hydrochloride | small molecules | EMA | — | Laboratoires Delbert |
4-((L-valyl)oxy)butanoic acid | small molecules | FDA | — | Avadel CNS Pharmaceuticals, LLC |
reboxetine | small molecules | FDA | Axsome Therapeutics, Inc. | |
sodium oxybate [Lumryz] | small molecules | FDA | Approved | Flamel Ireland Limited dba Avadel Ireland |
methyl (2R,3S)-3-[(methylsulfonyl)amino]-2-{[(cis-4-phenylcyclohexyl)oxy]methyl}piperidine-1-carboxylate | small molecules | FDA | Takeda Development Center Americas, Inc. | |
pentetrazol | small molecules | FDA | Balance Therapeutics, Inc. | |
fixed dose combination of modafinil and flecainide | small molecules | FDA | Theranexus S.A | |
mazindol | small molecules | FDA | NLS-0 Pharma AG | |
Mazindol | small molecules | EMA | Propharma Group The Netherlands B.V. | |
Mazindol [Diminex] | small molecules | EMA | [INACTIVE] H.A.C. Pharma | |
Solriamfetol [Sunosi] | small molecules | FDA | Approved | Axsome Malta, Ltd. |
Pitolisant [WAKIX] | small molecules | FDA | Approved | Harmony Biosciences Management, Inc. |
pitolisant [WAKIX®] | small molecules | FDA | Approved | Harmony Biosciences Management, Inc. |
pitolisant [Wakix] | small molecules | FDA | Approved | Harmony Biosciences, LLC |
1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride [Wakix] | small molecules | EMA | Approved | Bioprojet Pharma |
Sodium oxybate [Xyrem] | small molecules | EMA | UCB Pharma Limited | |
calcium, magnesium, potassium, and sodium oxybates [Xywav] | small molecules | FDA | Approved | Jazz Pharmaceuticals Ireland Limited |
sodium oxybate [Xyrem] | small molecules | FDA | Approved | Jazz Pharmaceuticals Ireland Limited |
Modafinil [Provigil] | small molecules | FDA | Approved | Cephalon, Inc. |
Gamma hydroxybutyrate | small molecules | FDA | Biocraft Laboratories, Inc. | |
Gamma-hydroxybutyric acid | small molecules | FDA | Sigma Chemical Company | |
viloxazine HCL | small molecules | FDA | — | Stuart Pharmaceuticals |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.